FDA — authorised 2 September 1954
- Application: NDA009470
- Marketing authorisation holder: FRESENIUS KABI USA
- Local brand name: XYLOCAINE VISCOUS
- Indication: SOLUTION — ORAL
- Status: approved
🇺🇸 Lidocaine post-embolization in United States
FDA authorised Lidocaine post-embolization on 2 September 1954
Marketing authorisations
FDA — authorised 11 March 1958
- Application: NDA010496
- Marketing authorisation holder: ASTRAZENECA
- Local brand name: XYLOCAINE 5% W/ GLUCOSE 7.5%
- Indication: INJECTABLE — SPINAL
- Status: approved
FDA — authorised 7 May 1959
- Application: NDA010417
- Marketing authorisation holder: FRESENIUS KABI USA
- Local brand name: XYLOCAINE 4% PRESERVATIVE FREE
- Indication: SOLUTION — TOPICAL
- Status: approved
FDA — authorised 15 September 1964
- Application: ANDA060567
- Marketing authorisation holder: PFIZER
- Local brand name: TERRAMYCIN
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 6 October 1969
- Application: NDA016801
- Marketing authorisation holder: FRESENIUS KABI USA
- Local brand name: XYLOCAINE PRESERVATIVE FREE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 14 February 1972
- Application: ANDA080407
- Marketing authorisation holder: WEST-WARD PHARMS INT
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 15 February 1972
- Application: ANDA080420
- Marketing authorisation holder: ABRAXIS PHARM
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 23 February 1972
- Application: ANDA080504
- Marketing authorisation holder: BELMORA LLC
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 6 April 1972
- Application: ANDA080409
- Marketing authorisation holder: HOSPIRA
- Local brand name: LTA II KIT
- Indication: SOLUTION — TOPICAL
- Status: approved
FDA — authorised 31 October 1972
- Application: ANDA083158
- Marketing authorisation holder: HOSPIRA
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 27 December 1972
- Application: ANDA083198
- Marketing authorisation holder: LUITPOLD
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 11 December 1973
- Application: ANDA080760
- Marketing authorisation holder: BEL MAR
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 11 December 1973
- Application: ANDA080710
- Marketing authorisation holder: BEL MAR
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 11 April 1974
- Application: ANDA080429
- Marketing authorisation holder: BIONPHARMA
- Local brand name: ANESTACON
- Indication: JELLY — TOPICAL
- Status: approved
FDA — authorised 18 March 1975
- Application: ANDA083388
- Marketing authorisation holder: DELL LABS
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 18 March 1975
- Application: ANDA083387
- Marketing authorisation holder: DELL LABS
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 28 March 1975
- Application: NDA017549
- Marketing authorisation holder: MERIDIAN MEDCL TECHN
- Local brand name: LIDOPEN
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 30 April 1975
- Application: ANDA084626
- Marketing authorisation holder: ELKINS SINN
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 29 August 1975
- Application: ANDA083083
- Marketing authorisation holder: WYETH AYERST
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 17 September 1975
- Application: ANDA083173
- Marketing authorisation holder: INTL MEDICATION
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 7 October 1975
- Application: ANDA084721
- Marketing authorisation holder: CARLISLE
- Local brand name: ALPHACAINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 29 July 1976
- Application: ANDA085037
- Marketing authorisation holder: EPIC PHARMA LLC
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 27 October 1976
- Application: NDA017508
- Marketing authorisation holder: ABRAXIS PHARM
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 29 October 1976
- Application: ANDA085131
- Marketing authorisation holder: ELKINS SINN
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 3 December 1976
- Application: NDA017701
- Marketing authorisation holder: INTL MEDICATION
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 14 March 1977
- Application: ANDA080390
- Marketing authorisation holder: LYPHOMED
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 17 November 1977
- Application: ANDA085995
- Marketing authorisation holder: HOSPIRA
- Local brand name: PEDIATRIC LTA KIT
- Indication: SOLUTION — TOPICAL
- Status: approved
FDA — authorised 14 December 1979
- Application: ANDA086761
- Marketing authorisation holder: ABRAXIS PHARM
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 6 March 1980
- Application: ANDA086364
- Marketing authorisation holder: INTL MEDICATION
- Local brand name: LARYNG-O-JET KIT
- Indication: SOLUTION — TOPICAL
- Status: approved
FDA — authorised 9 May 1980
- Application: ANDA086578
- Marketing authorisation holder: ACTAVIS MID ATLANTIC
- Local brand name: LIDOCAINE HYDROCHLORIDE VISCOUS
- Indication: SOLUTION — ORAL
- Status: approved
FDA — authorised 19 December 1980
- Application: NDA018388
- Marketing authorisation holder: HOSPIRA
- Local brand name: LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 2 February 1982
- Application: ANDA086389
- Marketing authorisation holder: INTL MEDICATION
- Local brand name: LIDOCAINE HYDROCHLORIDE VISCOUS
- Indication: SOLUTION — ORAL
- Status: approved
FDA — authorised 9 August 1982
- Application: ANDA083135
- Marketing authorisation holder: GD SEARLE LLC
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 18 November 1982
- Application: ANDA087872
- Marketing authorisation holder: PHARMOBEDIENT
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: SOLUTION — ORAL
- Status: approved
FDA — authorised 18 November 1982
- Application: ANDA087881
- Marketing authorisation holder: PHARMOBEDIENT
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: SOLUTION — TOPICAL
- Status: approved
FDA — authorised 2 February 1983
- Application: ANDA087980
- Marketing authorisation holder: ABBOTT
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 10 June 1983
- Application: ANDA087931
- Marketing authorisation holder: KENDALL IL
- Local brand name: LARYNGOTRACHEAL ANESTHESIA KIT
- Indication: SOLUTION — TOPICAL
- Status: approved
FDA — authorised 17 August 1983
- Application: ANDA084727
- Marketing authorisation holder: PHARMATON
- Local brand name: LIDOCATON
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 16 May 1984
- Application: ANDA088294
- Marketing authorisation holder: HOSPIRA
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 17 May 1984
- Application: ANDA088330
- Marketing authorisation holder: HOSPIRA
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 17 May 1984
- Application: ANDA088328
- Marketing authorisation holder: HOSPIRA
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 17 May 1984
- Application: ANDA088329
- Marketing authorisation holder: HOSPIRA
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 17 May 1984
- Application: ANDA088331
- Marketing authorisation holder: HOSPIRA
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 31 July 1984
- Application: ANDA088572
- Marketing authorisation holder: ABBOTT
- Local brand name: PEDIATRIC LTA KIT
- Indication: SOLUTION — TOPICAL
- Status: approved
FDA — authorised 31 July 1984
- Application: ANDA088542
- Marketing authorisation holder: HOSPIRA
- Local brand name: LTA II KIT
- Indication: SOLUTION — TOPICAL
- Status: approved
FDA — authorised 9 July 1985
- Application: NDA018954
- Marketing authorisation holder: ABBOTT
- Local brand name: LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 24 July 1985
- Application: ANDA088586
- Marketing authorisation holder: FRESENIUS KABI USA
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 25 May 1988
- Application: ANDA089362
- Marketing authorisation holder: ABBOTT
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 30 June 1989
- Application: ANDA089688
- Marketing authorisation holder: PACO
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: SOLUTION — TOPICAL
- Status: approved
FDA — authorised 8 April 1992
- Application: NDA019830
- Marketing authorisation holder: B BRAUN
- Local brand name: LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 29 April 1993
- Application: ANDA081318
- Marketing authorisation holder: COSETTE
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: JELLY — TOPICAL
- Status: approved
FDA — authorised 23 June 1995
- Application: ANDA040013
- Marketing authorisation holder: HOSPIRA
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 23 June 1995
- Application: ANDA040078
- Marketing authorisation holder: HOSPIRA
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 10 July 1995
- Application: ANDA040014
- Marketing authorisation holder: HIKMA
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: SOLUTION — ORAL
- Status: approved
FDA — authorised 28 September 1998
- Application: ANDA040302
- Marketing authorisation holder: HOSPIRA
- Local brand name: LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 12 February 2003
- Application: ANDA040433
- Marketing authorisation holder: SENTISS
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: JELLY — TOPICAL
- Status: approved
FDA — authorised 27 February 2007
- Application: ANDA040708
- Marketing authorisation holder: CHARTWELL MOLECULAR
- Local brand name: LIDOCAINE HYDROCHLORIDE VISCOUS
- Indication: SOLUTION — ORAL
- Status: approved
FDA — authorised 27 February 2007
- Application: ANDA040710
- Marketing authorisation holder: LANNETT CO INC
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: SOLUTION — TOPICAL
- Status: approved
FDA — authorised 23 March 2011
- Application: ANDA040837
- Marketing authorisation holder: WATSON LABS INC
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: JELLY — TOPICAL
- Status: approved
FDA — authorised 12 March 2014
- Application: ANDA204494
- Marketing authorisation holder: PAI HOLDINGS PHARM
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: SOLUTION — TOPICAL
- Status: approved
FDA — authorised 11 April 2014
- Application: ANDA202242
- Marketing authorisation holder: RISING
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 28 April 2014
- Application: ANDA201094
- Marketing authorisation holder: SAGENT PHARMS INC
- Local brand name: GLYDO
- Indication: JELLY — TOPICAL
- Status: approved
FDA — authorised 14 August 2015
- Application: ANDA091564
- Marketing authorisation holder: AM REGENT
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 30 October 2017
- Application: ANDA207182
- Marketing authorisation holder: EUGIA PHARMA
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 18 April 2018
- Application: ANDA208017
- Marketing authorisation holder: SPECTRA MDCL DEVICES
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 3 August 2018
- Application: ANDA208474
- Marketing authorisation holder: B BRAUN MEDICAL
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 7 May 2020
- Application: ANDA212821
- Marketing authorisation holder: HUONS
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 8 November 2021
- Application: ANDA214336
- Marketing authorisation holder: ASPIRO
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 8 November 2021
- Application: ANDA214339
- Marketing authorisation holder: ASPIRO
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 23 March 2022
- Application: ANDA216250
- Marketing authorisation holder: NOVITIUM PHARMA
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: SOLUTION — TOPICAL
- Status: approved
FDA — authorised 9 June 2022
- Application: ANDA215132
- Marketing authorisation holder: AFAXYS
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 16 June 2023
- Application: ANDA217692
- Marketing authorisation holder: MANKIND PHARMA
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 11 July 2023
- Application: ANDA217693
- Marketing authorisation holder: MANKIND PHARMA
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 7 December 2023
- Application: ANDA218182
- Marketing authorisation holder: SUN PHARMA CANADA
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: SOLUTION — TOPICAL
- Status: approved
FDA — authorised 29 April 2024
- Application: ANDA218411
- Marketing authorisation holder: THE J MOLNER
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: SOLUTION — TOPICAL
- Status: approved
FDA — authorised 2 April 2025
- Application: ANDA219535
- Marketing authorisation holder: ANTHEA PHARMA
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 29 July 2025
- Application: ANDA219759
- Marketing authorisation holder: AUROBINDO PHARMA LTD
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: SOLUTION — ORAL
- Status: approved
FDA — authorised 19 March 2026
- Application: ANDA220071
- Marketing authorisation holder: VIWIT PHARM
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 20 March 2026
- Application: ANDA218676
- Marketing authorisation holder: QUAGEN
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: SOLUTION — ORAL
- Status: approved
FDA
- Application: ANDA080414
- Marketing authorisation holder: MILES
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA
- Application: ANDA083627
- Marketing authorisation holder: WATSON LABS
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA
- Status: approved
FDA
- Application: NDA018543
- Marketing authorisation holder: INTL MEDICATION
- Local brand name: LIDOCAINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
Lidocaine post-embolization in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Lidocaine post-embolization approved in United States?
Yes. FDA authorised it on 2 September 1954; FDA authorised it on 11 March 1958; FDA authorised it on 7 May 1959.
Who is the marketing authorisation holder for Lidocaine post-embolization in United States?
FRESENIUS KABI USA holds the US marketing authorisation.